Article

Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats

Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri 63110, USA.
Journal of Nuclear Medicine (Impact Factor: 5.56). 12/1998; 39(11):1944-51.
Source: PubMed

ABSTRACT The efficacy of 64Cu [T1/2 = 12.7 hr; beta+ (0.655 MeV; 19%); beta- (0.573 MeV; 40%)] as a radioisotope for radiotherapy has been recently established. Here we demonstrate that 64Cu-1,4,8,11 -tetraazacyclotetradecane-N,N',N",N'''-tetraacetic acid (TETA)-octreotide, a somatostatin receptor ligand, inhibits the growth of CA20948 rat pancreatic tumors in Lewis rats at doses that cause minimal toxicity.
Tumor-bearing rats were administered a single 15 mCi (555 MBq) dose, a fractionated dose of 15 mCi given in 2-3 doses over 2-8 days, or control agents of buffer, unlabeled octreotide or 64Cu-labeled TETA. In certain experiments, blood was removed at times from 4-23 days post-treatment, and a complete blood count along with blood chemistry analyses were obtained.
Tumor-growth inhibition was significantly greater in rats injected with a single 15 mCi dose than in rats injected with control agents (p < 0.05). Dose fractionation in two doses, either 1 or 2 days apart, induced significantly increased tumor-growth inhibition compared with rats given a single dose (p < 0.05). The only toxicity observed in treated rats was a decrease in the white blood cell count. This drop was more pronounced in rats treated with a single dose compared with those treated with a fractionated dose. Human absorbed doses of 64Cu-TETA-octreotide to normal organs were estimated from biodistribution data in Lewis rats, and these data indicate that radiotherapy with 64Cu-TETA-octreotide in humans would be feasible.
Copper-64-TETA-octreotide is a promising radiopharmaceutical for targeted radiotherapy of somatostatin receptor-positive tumors.

Download full-text

Full-text

Available from: Carolyn J Anderson, Jul 01, 2014
0 Followers
 · 
138 Views
  • Source
    • "Animals weighing 25-30 g received a 500 μCi (~18 MBq) intravenous injection of 64Cu-PPF. Cu toxicity is not a concern as the dose used for PET studies (500 μCi, ~18 MBq) is far lower than those used for radiotherapy studies in which a 10 mCi (~370 MBq) of 64Cu has been administered in murine models with no overt toxicity reported 27-29. MicroPET imaging and MicroCT scans were performed accordingly at 4 and 24 h post-injection. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Porphyrin based photosensitizers are useful agents for photodynamic therapy (PDT) and fluorescence imaging of cancer. Porphyrins are also excellent metal chelators forming highly stable metallo-complexes making them efficient delivery vehicles for radioisotopes. Here we investigated the possibility of incorporating (64)Cu into a porphyrin-peptide-folate (PPF) probe developed previously as folate receptor (FR) targeted fluorescent/PDT agent, and evaluated the potential of turning the resulting (64)Cu-PPF into a positron emission tomography (PET) probe for cancer imaging. Noninvasive PET imaging followed by radioassay evaluated the tumor accumulation, pharmacokinetics and biodistribution of (64)Cu-PPF. (64)Cu-PPF uptake in FR-positive tumors was visible on small-animal PET images with high tumor-to-muscle ratio (8.88 ± 3.60) observed after 24 h. Competitive blocking studies confirmed the FR-mediated tracer uptake by the tumor. The ease of efficient (64)Cu-radiolabeling of PPF while retaining its favorable biodistribution, pharmacokinetics and selective tumor uptake, provides a robust strategy to transform tumor-targeted porphyrin-based photosensitizers into PET imaging probes.
    Theranostics 09/2011; 1:363-70. · 7.83 Impact Factor
  • Source
    • "Biodistribution and metabolism studies of 64 Cu-labeled DOTA/TETA monoclonal antibody or peptide conjugates have demonstrated significant dissociation of the 64 Cu from the bifunctional chelator resulting in transchelation to liver superoxide dismutase and other proteins [24,27,42–44]. 64 Cu-labeled DOTA/TETA conjugates often show poor blood and liver clearance, high uptake in some nontarget organs and increased background radioactivity levels, resulting in reduced imaging sensitivity, poor image quality and radiation toxicity [45] [46]. A series of copper(II) cross-bridged cyclam complexes have been synthesized and characterized, and have demonstrated improved kinetic stability compared with TETA and DOTA complexes [26] [47]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The alpha(v)beta(3) integrin is a cell adhesion molecule known to be involved in stages of angiogenesis and metastasis. In this study, the chelators CB-TE2A and diamsar were conjugated to cyclic RGDyK and RGDfD and the biological properties of (64)Cu-labeled peptides were compared. CB-TE2A-c(RGDyK) and diamsar-c(RGDfD) were labeled with (64)Cu in 0.1 M NH(4)OAc (pH=8) at 95 degrees C and 25 degrees C, respectively. PET and biodistribution studies were carried out on M21 (alpha(v)beta(3)-positive) and M21L (alpha(v)-negative) melanoma-bearing mice. Binding affinity of the Cu-chelator-RGD peptides to alpha(v)beta(3) integrins was determined by a competitive binding affinity assay. Biological studies showed higher concentration of (64)Cu-CB-TE2A-c(RGDyK) in M21 tumor compared to M21L tumor at 1 and 4 h pi. Tumor concentration of (64)Cu-CB-TE2A-c(RGDyK) was higher than that of (64)Cu-diamsar-c(RGDfD). The difference is not due to differing binding affinities, since similar values were obtained for the agents. Compared to (64)Cu-diamsar-c(RGDfD), there is more rapid liver and blood clearance of (64)Cu-CB-TE2A-c(RGDyK), resulting in a lower liver and blood concentration at 24 h pi. Both (64)Cu-labeled RGD peptides show similar binding affinities to alpha(v)beta(3). The differences in their biodistribution properties are likely related to different linkers, charges and lipophilicities. The M21 tumor is clearly visualized with (64)Cu-CB-TE2A-c(RGDyK) by microPET imaging. Administration of c(RGDyK) as a block significantly reduced the tumor concentration; however, the radioactivity background was also decreased by the blocking dose. Both (64)Cu-CB-TE2A-c(RGDyK) and (64)Cu-diamsar-c(RGDfD) are potential candidates for imaging tumor angiogenesis. For diamsar-c(RGDfD), a linker may be needed between the Cu-chelator moiety and the RGD peptide to achieve optimal in vivo tumor concentration and clearance from nontarget organs.
    Nuclear Medicine and Biology 05/2009; 36(3):277-85. DOI:10.1016/j.nucmedbio.2008.12.008 · 2.41 Impact Factor
  • Source
    • "Copper-64 (T 1/2 = 12.7 h; b + : 0.653 MeV, 17.4%; b À : 0.578 MeV, 39%) has shown its versatility in both positron emission tomography (PET) imaging [1] [2] [3] [4] [5] [6] [7] and radiotherapy [8] [9] [10] [11] [12] [13], due to its decay characteristics and the ability for its large-scale production with high specific activity on a biomedical cyclotron [14]. In the development of copper radiopharmaceuticals, tetraazamacrocyclic ligands such as 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra- acetic acid (DOTA) have been traditionally preferred over acyclic chelators, such as diethylenetetraaminepentaacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Copper-64 (T(1/2)=12.7 h; beta(+): 0.653 MeV, 17.4%; beta(-): 0.578 MeV, 39%) has applications in positron emission tomography (PET) imaging and radiotherapy, and is conveniently produced on a biomedical cyclotron. Tetraazamacrocyclic ligands are the most widely used bifunctional chelators (BFCs) for attaching copper radionuclides to antibodies and peptides due to their relatively high kinetic stability. In this paper, we evaluated three monooxo-tetraazamacrocyclic ligands with different ring sizes and oxo group positions. H1 [1,4,7,10-tetraazacyclotridecan-11-one], H2 [1,4,8,11-tetraazacyclotetradecan-5-one] and H3 [1,4,7,10-tetraazacyclotridecan-2-one] were radiolabeled with (64)Cu in high radiochemical yields under mild conditions. The three (64)Cu-labeled complexes are all +1 charged, as determined by their electrophoretic mobility. While they demonstrated >95% stability in rat serum out to 24 h, both biodistribution and microPET imaging studies revealed high uptake and long retention of the compounds in major clearance organs (e.g., blood, liver and kidney), which suggests that (64)Cu dissociated from the complexes in vivo. Of the three complexes, (64)Cu-2(+), which has a cyclam backbone (1,4,8,11-tetraazacyclotetradecane), exhibited the lowest nontarget organ accumulation. The data from these studies may invalidate the candidacy of the monooxo-tetraazamacrocyclics as BFCs for copper radiopharmaceuticals. However, the data presented here suggest that neutral or negatively charged Cu(II) complexes of tetraazamacrocyclic ligands with a cyclam backbone (tetradecane) are optimal for copper radiopharmaceutical applications.
    Nuclear Medicine and Biology 12/2004; 31(8):1051-9. DOI:10.1016/j.nucmedbio.2004.08.011 · 2.41 Impact Factor
Show more